Business Description
Beam Therapeutics is a Cambridge, Massachusetts-based biotech company founded in 2017 that develops targeted gene-editing treatments for patients with serious inherited conditions. The company is advancing a pipeline of therapies for blood disorders and genetic diseases, including treatments for sickle cell disease, alpha-1 antitrypsin deficiency, and several rare liver conditions. Beam also works with partners such as Pfizer, Verve Therapeutics, and Orbital Therapeutics to expand its gene-editing research across the liver, muscle, and nervous system.
